MMP-9 activity in urine from patients with various tumors, as measured by a novel MMP activity assay using modified urokinase as a substrate

Annals of the New York Academy of Sciences

Volumn 878, Issue , 1999, Pages 141-149

  Hanemaaijer, R ^a   Sier, C F M ^b   Visser, H ^a   Scholte, L ^a   Van Lent, N ^a   Toet, K ^a   Hoekman, K ^c   Verheijen, J H ^a  

^a TNO   (Netherlands)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; PLASMIN; UROKINASE;

ADULT; BLADDER CARCINOMA; BREAST CANCER; CANCER; CONFERENCE PAPER; CONTROLLED STUDY; DIAGNOSTIC APPROACH ROUTE; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME SPECIFICITY; ESOPHAGUS CANCER; HUMAN; LUNG CANCER; OVARY CANCER; URINALYSIS;

EID: 0032837901     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1999.tb07680.x     Document Type: Conference Paper

References (33)

1. 1. Stetler-Stevenson, W.G., L.A. Liotta & D.E. Kleiner. 1993. Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J. 7: 1434-1441.
2. 2. Ray, J.M. & W.G. Stetler-Stevenson. 1994. The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur. Resp. J. 7: 2062-2072.
3. 3. Duffy, M.J. & K. McCarthy. 1998. Matrix metalloproteinases in cancer: prognostic markers and targets for therapy. Int. J. Oncol. 12: 1343-1348.
4. 4. Sier, C.F.M., F.J.G.M. Kubben, S. Ganesh, M.M. Heerding, G. Griffioen, R. Hanemaaijer, J.H.J.M. Van Krieken, C.B.H.W. Lamers & H.W. Verspaget. 1996. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br. J. Cancer 74: 413-417.
5. 5. Davies, B., J. Waxman, H. Wasan, P. Abel, G. Williams, T. Krausz, D. Neal, D. Thomas, A. Hanby & F. Balkwill. 1993. Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res. 53: 5365-5369.
6. 6. Kawamata, H., S. Kameyama, K. Kawai, Y. Tanaka, L. Nan, D.H. Barch, W.G. Stetler-Stevenson & R. Oyasu. 1995. Marked acceleration of the metastatic phenotype of a rat bladder carcinoma cell line by the expression of human gelatinase A. Int. J. Cancer 63: 568-575.
7. 7. Gohji, K., N. Fujimoto, T. Komiyama, A. Fujh, J. Ohkawa, S. Kamidono & M. Nakajima. 1996. Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictors of recurrence in patients with urothelial carcinoma. Cancer 78: 2379-2387.
8. 8. Gohji, K., N. Fujimoto, I. Hara, A. Fujh, A. Gotoh, H. Okada, S. Arakawa, S. Kitazawa, H. Miyake, S. Kamidono & M. Nakajima. 1998. Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension. Int. J. Cancer 79: 96-101.
9. 9. Berend, K.R., A.P. Toth, J.M. Harrelson, L.J. Layfield, L.A. Hey & S.P. Scully. 1998. Association between ratio of matrix metalloproteinase-1 to tissue inhibitor of metalloproteinase-1 and local recurrence, metastasis, and survival in human chondrosarcoma. J. Bone Joint Surg. Am. 80: 11-17.
10. 10. Munck-Wikland, E., K. Heselmeyer, J. Lindholm, R. Kuylenstierna, G. Auer & G. Engel. 1998. Stromelysin-3 mRNA expression in dysplasias and invasive epithelial cancer of the larynx. Int. J. Oncol. 12: 859-864.
11. 11. Murray, G.I., M.E. Duncan, P. O'Neil, W.T. Melvin & J.E. Fothergill. 1996. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat. Med. 2: 461-462.
12. 12. Allgayer, H., R. Babic, B.C. Beyer, K.U. Grutzner, A. Tarabichi, F.W. Schildberg & M.M. Heiss. 1998. Prognostic relevance of MMP-2 (72-kD collagenase IV) in gastric cancer. Oncology 55: 152-160.
13. 13. Vaisanen, A., H. Tuominen, M. Kallioinen & T. Turpeenniemi-Hujanen. 1996. Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumor progression and may have prognostic value. J. Pathol. 180: 283-289.
14. 14. Zucker, S., R.M. Lysik, M.H. Zarrabi & U. Moll. 1993. Mr 92.000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res. 53: 140-146.
15. 15. Baker, T., S. Tickle, H. Wasan, A. Docherty, D. Isenberg & J. Waxman. 1994 Serum metalloproteinases and their inhibitors: markers for malignant potential. Br. J. Cancer 70: 506-512.
16. 16. Torh, A., Y. Kodera, K. Uesaka, T. Hirai, K. Yasui, T. Morimoto, Y. Yamamura, T. Kato, T. Hayakawa, N. Fujimoto & T. Kito. 1997. Plasma concentration of matrix metalloproteinase 9 in gastric cancer. Br. J. Surg. 84: 133-136.
17. 17. Jung, K., C. Laube, M. Lein, R. Lichtinghagen, H. Tschesche, D. Schnorr & S.A. Loenig. 1998. Kind of sample as preanalytical determinant of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood. Clin. Chem. 44: 1060-1062.
18. 18. Margulies, I.M., M. Hoyhtya, C. Evans, M.L. Stracke, L.A. Liotta & W.G. Stetler-Stevenson. 1992. Urinary type IV collagenase: elevated levels are associated with bladder transitional carcinoma. Cancer Epidemiol. Biomark. Prev. 1: 467-474.
19. 19. Moses, M.A., D. Wiederschain, K.R. Loughlin, D. Zurakowski, C.C. Lamb & M.R. Freeman. 1998 Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res. 58: 1395-1399.
20. 20. Verheijen, J.H., N.M.E. Nieuwenbroek, B. Beekman, R. Hanemaaijer, H.W. Verspaget, H.K. Ronday & A.H.F. Bakker. 1997. Modified proenzymes as artificial substrates for proteolytic enzymes: colorimetric assay of bacterial collagenase and matrix metalloproteinase activity using modified pro-urokinase. Biochem. J. 323: 603-609.
21. 21. Hanemaaijer, R., H. Visser, Y. Konttinen, P. Koolwijk & J.H. Verheijen. 1998. A novel and simple immunocapture assay for determination of gelatinase-B (MMP-9) activities in biological fluids: saliva from patients with Sjögren's syndrome contain increased latent and active gelatinase-B levels. Matrix Biol. 17: 657-665.
22. 22. Hanemaaijer, R., P. Koolwijk, L. Le Clercq, W.J.A. De Vree & V.W.M. Van Hinsbergh. 1993. Regulation of matrix metalloproteinase (MMP) regulation in human vein and microvascular endothelial cells. Biochem. J. 296: 803-809.
23. 23. Hanemaaijer, R., T. Sorsa, Y.T. Konttinen, Y. Ding, M. Kylmäniemi, H. Visser, V.W.M. Van Hinsbergh, T. Helaakoski, T. Kainulainen, H. Rönkä, H. Tschesche & T. Salo. 1997. Matrix metalloproteinase-8 is expressed in rheumatoid synovial fibroblasts and endothelial cells: regulation by TNFγ and doxycycline. J. Biol. Chem. 272: 31504-31509.
24. 24. Koolwijk, P., M.G.M. Van Erck, W.J.A. De Vree, M.A. Vermeer, H.A. Weich, R. Hanemaaijer & V.W.M. Van Hinsbergh. 1996. Cooperative effect of TNFα, bFGF and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix: role of urokinase activity. J. Cell Biol. 132: 1177-1188.
25. 25. Kleiner, D.E. & W.G. Stetler-Stevenson. 1994. Quantitative zymography: detection of picogram quantities of gelatinases. Anal. Biochem. 218: 325-329.
26. 26. Nagase, H. & G. Fields. 1996. Human matrix metalloproteinase specificity studies using collagen sequence-based synthetic peptides. Biopolymers 40: 399-341.
27. 27. Beekman, B., J. Drijfhout, W. Bloemhoff, H. Ronday, P. Tak & J. Koppele. 1996. Convenient fluorometric assay for matrix metalloproteinase activity and its application in biological media. FEBS Lett. 390: 221-225.
28. 28. Khokha, R. 1994. Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1. J. Natl. Cancer Inst. 86: 299-304.
29. 29. Naruo, S., H. Kanayama, H. Takigawa, S. Kagawa, K. Yamashita & T. Hayakawa. 1994. Serum levels of a tissue inhibitor of metalloproteinases-1 (TIMP-1) in bladder cancer patients. Int. J. Urol. 1: 228-231.
30. 30. Dengler, R., T. Lah, D. Gabrijelcic, V. Turk, H. Fritz & B. Emmerich. 1991. Detection of cathepsin-B in tumor cytosol and urine of breast cancer patients. Biom. Biochim. Acta 50: 555-560.
31. 31. Aoki, T., T. Takasaki, J. Morikawa, T. Yano & H. Watabe. 1994. Electrophoretic analysis of a gastric cancer-associated acid proteinase using a highly sensitive detection system. Biol. Pharm. Bull. 17: 1358-1363.
32. 32. O'Reilly, M.S., L. Holmgren, C. Chen & J. Folkman. 1996. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med. 2: 689-692.
33. 33. O'Reilly, M.S., L. Holmgren, Y. Shing, C. Chen, R.A. Rosenthal, M. Moses, W.S. Lane, Y. Cao, E.H. Sage & J. Folkman. 1994. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315-328.